C Fabregat-Franco1, A Stradella2, V Navarro3, J Linares2, M Galdeano4, S Recalde2, R Velasco5, M Simo5, A Fernadez2, A C Venthecourt2, C Falo2, S Vazquez2, M Bergamino2, R Villanueva2, S Pernas2, M J Gil-Gil2. 1. Medical Oncology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, Av Gran Via de L'Hospitalet, 199-203 L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. cfabregat@iconcologia.net. 2. Medical Oncology Department, Catalan Institute of Oncology, Duran i Reynals Hospital, Av Gran Via de L'Hospitalet, 199-203 L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. 3. Clinical Research Unit, Catalan Institute of Oncology, Av Gran Via de L'Hospitalet, L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. 4. Radiotherapy Oncology Department, Catalan Institute of Oncology, Av Gran Via de L'Hospitalet, L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain. 5. Neuro-Oncology Unit, Catalan Institute of Oncology, Av Gran Via de L'Hospitalet, L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.
Abstract
PURPOSE: Brain metastases (BM) occur in 15-35% of patients with metastatic breast cancer, conferring poor prognosis and impairing quality of life. Clinical scores have been developed to classify patients according to their prognosis. We aimed to check the utility of the Breast Graded Prognostic Assessment (B-GPA) and its modified version (mB-GPA) and compare them in routine clinical practice. METHODS: This is an ambispective study including all patients with breast cancer BM treated in a single cancer comprehensive center. We analyzed the overall survival (OS) from BM diagnosis until death. The Kaplan-Meier method and Cox proportional hazard regression model were used in the analyses. ROC curves were performed to compare both scores. RESULTS: We included 169 patients; median age was 50 years. HER2-positive and triple negative patients were 33.7% and 20.7%, respectively. At the last follow-up, 90% of the patients had died. Median OS was 12 months (95% confidence interval 8.0-16.0 months). OS was worse in patients with > 3 BM and in patients with triple negative subtype. CONCLUSIONS: In our series, we confirm that B-GPA and mB-GPA scores correlated with prognosis. ROC curves showed that B-GPA and mB-GPA have similar prognostic capabilities, slightly in favor of mB-GPA.
PURPOSE: Brain metastases (BM) occur in 15-35% of patients with metastatic breast cancer, conferring poor prognosis and impairing quality of life. Clinical scores have been developed to classify patients according to their prognosis. We aimed to check the utility of the Breast Graded Prognostic Assessment (B-GPA) and its modified version (mB-GPA) and compare them in routine clinical practice. METHODS: This is an ambispective study including all patients with breast cancer BM treated in a single cancer comprehensive center. We analyzed the overall survival (OS) from BM diagnosis until death. The Kaplan-Meier method and Cox proportional hazard regression model were used in the analyses. ROC curves were performed to compare both scores. RESULTS: We included 169 patients; median age was 50 years. HER2-positive and triple negative patients were 33.7% and 20.7%, respectively. At the last follow-up, 90% of the patients had died. Median OS was 12 months (95% confidence interval 8.0-16.0 months). OS was worse in patients with > 3 BM and in patients with triple negative subtype. CONCLUSIONS: In our series, we confirm that B-GPA and mB-GPA scores correlated with prognosis. ROC curves showed that B-GPA and mB-GPA have similar prognostic capabilities, slightly in favor of mB-GPA.
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: T Fokstuen; N Wilking; L E Rutqvist; J Wolke; A Liedberg; T Signomklao; J O Fernberg Journal: Breast Cancer Res Treat Date: 2000-08 Impact factor: 4.872
Authors: Ishwaria M Subbiah; Xiudong Lei; Jeffrey S Weinberg; Erik P Sulman; Mariana Chavez-MacGregor; Debu Tripathy; Rohan Gupta; Ankur Varma; Jay Chouhan; Richard P Guevarra; Vicente Valero; Mark R Gilbert; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2015-05-18 Impact factor: 44.544
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Nancy U Lin; Laleh Amiri-Kordestani; Diane Palmieri; David J Liewehr; Patricia S Steeg Journal: Clin Cancer Res Date: 2013-12-01 Impact factor: 12.531
Authors: Gaia Griguolo; William Jacot; Eva Kantelhardt; Maria Vittoria Dieci; Céline Bourgier; Christoph Thomssen; Caroline Bailleux; Federica Miglietta; Antoine-Laurent Braccini; PierFranco Conte; Jean Marc Ferrero; Valentina Guarneri; Amélie Darlix Journal: Breast Date: 2017-10-23 Impact factor: 4.380